Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 934 participants.

Also called NCT01121835

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 934 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01121835
  • EudraCT 2009-018172-33
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Austria, Brazil, China, Colombia, Denmark, Greece, India, Italy, Kuwait, Mexico, Romania, South Korea, Spain, Taiwan, Türkiye, United Arab Emirates (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01121835. Randomized; no masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2012-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study
Acronym
GALAPAGOS
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
INSULIN GLARGINE
Intervention (Drug)
INSULIN GLULISINE
Intervention (Drug)
PREMIXED INSULIN
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01121835
Content hash
9078d6097398ae2cf435fd9fce6e4472f47fbc17e2ffdc247d45a4480f224220